Pepaxti 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IAIN/0007 
A.1 - Administrative change - Change in the name 
27/11/2023 
and/or address of the MAH 
IB/0004 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
20/11/2023 
life of the finished product - As packaged for sale 
SmPC, 
Labelling and 
PL 
SmPC 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
(supported by real time data) 
PSUSA/11013
Periodic Safety Update EU Single assessment - 
31/08/2023 
n/a 
PRAC Recommendation - maintenance 
/202302 
melphalan flufenamide 
IB/0001 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
19/12/2022 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 2/2 
 
 
 
 
 
 
 
 
 
 
 
 
